REDWOOD CITY, Calif., April 29, 2011 /PRNewswire/ —
Pearl Therapeutics Inc. announced today that complete
results from the Company’s Phase 2b study of PT003
in patients with moderate-to-very severe COPD will be presented
during a late-breaker poster session at the upcoming annual meeting
of the American Thoracic Society (ATS). PT003 (GFF-MDI) is a
proprietary, fixed-dose combination of glycopyrrolate, a
long-acting muscarinic antagonist (LAMA), and formoterol, an
established, long-acting beta-2 agonist (LABA) delivered via a
pressurized hydrofluoroalkane metered dose inhaler (HFA MDI).
It is the first and only dual long-acting rapid
bronchodilator LAMA-LABA combination product in development in an
HFA MDI formulation, the most widely used inhalation drug delivery
format.
“Our presentation at this year’s ATS represents a particularly
important step in the progression of Pearl’s bronchodilator
franchise,” said Chuck
Bramlage, Pearl Therapeutics’ chief executive officer. “Not
only is it an opportunity to present our strong clinical evidence
to peers, but from a business perspective, it speaks to the speed
and fiscal efficiency with which Pearl has expedited the clinical
development of our lead bronchodilator combination and its
individual components. In fewer than four years since initial
financing, Pearl has completed the significant Phase 2b study being
highlighted at ATS, as well as other key clinical and non-clinical
studies. This is a testimonial to the Pearl team and its novel
co-suspension platform. We expect this momentum will continue
as we advance PT003 and its components, into a series of four
additional Phase 2b studies, and make plans for Phase 3 trials in
parallel.”
The ATS annual meeting is taking place May 13-18 in the Colorado
Convention Center in Denver, CO. Information regarding the ATS
presentations
‘/>”/>
SOURCE